Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--#CRIOM--Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18.

After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation–induced Oral Mucositis (CRIOM), Enzychem is actively negotiating licensing deals with several partnering candidates while also preparing a phase 3 trial under a US FDA IND. To reinforce such corporate initiatives, and to start supporting the company’s next stage activities, Enzychem has formed the Corporate Advisory Committee.

Enzychem Lifesciences recognizes the need for engagement of key opinion leaders at an earlier stage in the process of developing new therapeutics for a large population with high unmet needs such as Chemoradiation-induced Oral Mucositis (CRIOM). Enzychem is proactively bringing more experts to the company to strengthen its new drug development capabilities. The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives.

The four physicians appointed are Dr. Alexander Fleming, a former FDA reviewer and supervisory medical officer, as head of the metabolic group, Dr. Frank Castellana, a market value assessment expert, Dr. Joe McMenamin, a health lawyer, and Dr. Richard Hamrick, a former healthcare provider executive. Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones.

For two years, until 2018, Dr. Fleming served as Enzychem’s Chief Technology Officer (CTO). During his term, Dr. Fleming had recommended CRIOM as the lead indication for EC-18 and introduced Dr. Steve Sonis of Harvard School of Dental Medicine as Enzychem’s key advisor for the U.S. phase 2 CRIOM Study.

The four new corporate advisors are:

• Zan Fleming, MD
  • Former FDA reviewer and supervisory medical officer, CEO of Kinexum
  • Emory University School of Medicine; Vanderbilt University

• Frank Castellana, MD, Eng.Sc.D.
  • Former VP of Bristol-Myers Squibb
  • Albert Einstein College of Medicine; Columbia University

• Richard Hamrick, MD
  • Former Chief Medical Officer for HCA’s Capital Division.
  • Medical College of Virginia (Virginia Commonwealth University)

• Joe McMenamin, MD, JD
  • Former partner at McGuireWoods, LLP
  • Chief legal officer of W Medical Strategy Group
  • Penn Medical and Law Schools

About Enzychem Lifesciences

Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic, and inflammatory diseases. Founded in 1999, the company’s lead compound, EC-18, acts as an immunomodulator, facilitating the resolution of inflammation and the early return to immune homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. For more information, please visit www.enzychem.com.

Investors / Business Development
Ted Kim
Director of Business Development
ted.kim@enzychem.com

Media
Sanghyun Lee
Public Relations Associate
noah.lee@enzychem.com